Researchers sought to determine whether clearer guidelines are needed for utilizing ultrasounds to assess musculoskeletal outcomes in patients with hemophilia.
Researchers sought to determine whether combined training would improve lipid profiles and quality of life in patients with hemophilia A who were overweight.
People with hemophilia tend to have less adherence to prophylaxis as they transition to adulthood but continuing the therapy can improve their joint health.
Researchers sought to determine whether plasma-derived von Willebrand factor/factor VIII would be safe and effective in patients with hemophilia A younger than 12 years.
Researchers sought to determine whether recombinant VWF would be effective in reducing spontaneous bleeding for patients with severe VWD previously treated in an on-demand manner.
Researchers sought to determine whether valoctocogene roxaparvovec would reduce the risk of bleeding and rate of factor VIII infusion in patients with hemophilia A.
Acquired hemophilia A (AHA) and acquired von Willebrand syndrome (aVWS) are rare, life-threatening bleeding disorders that occur in patients with no bleeding history and no family history of a bleeding disorder.
Researchers sought to determine whether transfusing ABO-incompatible platelets would lead to worse clinical outcomes and slower platelet recovery in patients with ICH.
Researchers sought to determine whether clinical and ultrasound assessment tools generally agree in their determinations of joint health for children with hemophilia on prophylaxis.
Researchers sought to determine whether eculizumab discontinuation is feasible for patients with atypical hemolytic uremic syndrome when a strategy accounts for genetic variants.
Researchers sought to determine whether patients with moderate or severe hemophilia A may benefit from early prophylactic antihemophilic factor (recombinant).
Researchers sought to determine whether human fibrinogen concentrate would have favorable pharmacokinetics for adult, adolescent, and pediatric patients with congenital fibrinogen deficiency.
Hemophilia is a bleeding disorder caused by a genetic mutation that is often inherited. Patients who are at risk and parents or caregivers of children at risk of hemophilia may need additional education about what causes hemophilia and how it is diagnosed and treated.
Researchers conducted 2 sets of literature reviews to determine whether the professional society recommendations for >50% factor levels during labor in patients with hemophilia was accurate.
Researchers sought to determine whether recombinant factor VIII-Fc fusion protein would have greater efficacy as prophylaxis therapy over emicizumab in patients with hemophilia A.
Findings from a retrospective chart review showed a need to carefully monitor inflammatory biomarkers and anticoagulant dosage in patients with severe COVID-19.
Researchers performed an analysis to determine whether recombinant VWF given with surgery would be safe and effective in preventing bleeding in patients with VWD.
Researchers sought to determine whether physiotherapy and exercise would be an effective therapy for increasing functionality, joint health, and quality of life in patients with hemophilic arthropathy of the elbow.
DECKNonpharmacologic treatment with cognitive-behavioral therapy combined with physiotherapy may be an effective pain management strategy for patients with severe hemophilia.
Findings from a retrospective chart review showed a need to carefully monitor inflammatory biomarkers and anticoagulant dosage in patients with severe COVID-19.
Results of a rodent model show that fibrin-specific core-shell nanogels with a tissue-type plasminogen activator warrants more study as a treatment for patients with DIC.
Whether inherited or acquired, bleeding disorders can cause significant pain, inconvenience, and stress in a person’s life. When patients think they or a loved one may have a bleeding disorder, what should they know?
A group of US-based hemophilia experts summarized unmet needs in mild to moderate hemophilia and provided suggestions for healthcare professionals to optimally manage their patients with this challenging condition.
Pediatric patients with hemophilia may have impairments in postural balance, which could be an early sign of musculoskeletal disorders, and its assessment should be included in evaluations.
These guidelines from ASH, ISTH, NHF, and WFH are intended to support patients, clinicians, and healthcare professionals in their decisions affecting the management of VWD.
This study aimed to investigate the effects of manual therapy combined with home exercises for young adult patients with hemophilic arthropathy of the lower limb joints.
A team of investigators evaluated clinical characteristics, hemostasis management, and clinical outcomes of bleeding events in women and girls with hemophilia.
A population-based analysis suggested that plasma levels of von Willebrand factor may be a potential biomarker for the future risk of incident venous thromboembolism.
Among pediatric patients with congenital fibrinogen deficiency, the administration of human fibrinogen concentrate may be efficacious for on-demand treatment and surgical prophylaxis.
